Drug Profile
Research programme: antibody therapeutics - Numab/Intarcia
Alternative Names: Autoimmune disorders therapeutics - Numab/Intarcia; Diabetes therapeutics - Numab/Intarcia; ND 003; ND 007; ND 016; Obesity therapeutics - Numab/IntarciaLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Numab
- Developer Intarcia Therapeutics; Numab
- Class Antibodies; Bispecific antibodies
- Mechanism of Action CD3 antigen inhibitors; Interleukin 5 receptor antagonists; Interleukin-17 inhibitors; Th17 cell inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Autoimmune disorders; Diabetes mellitus; Inflammation; Obesity
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in Switzerland
- 28 Apr 2019 No recent reports of development identified for research development in Diabetes-mellitus in Switzerland
- 28 Apr 2019 No recent reports of development identified for research development in Obesity in Switzerland